Briacell Therapeutics Corp Stock Today
| BCTX Stock | USD 1.08 0.11 9.24% |
Performance10 of 100
| Odds Of DistressOver 73
|
Briacell Therapeutics is trading at 1.08 as of the 11th of December 2024; that is 9.24% down since the beginning of the trading day. The stock's open price was 1.19. Briacell Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 11th of November 2024 and ending today, the 11th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of February 2021 | Category Healthcare | Classification Health Care |
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. BriaCell Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 36.18 M outstanding shares of which 534.83 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover. More on Briacell Therapeutics Corp
Moving together with Briacell Stock
Moving against Briacell Stock
Briacell Stock Highlights
| President CEO | William MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBriacell Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Briacell Therapeutics' financial leverage. It provides some insight into what part of Briacell Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Briacell Therapeutics Corp (BCTX) is traded on NASDAQ Exchange in USA. It is located in Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 and employs 4 people. Briacell Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.31 M. Briacell Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.18 M outstanding shares of which 534.83 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover.
Briacell Therapeutics Corp currently holds about 41.04 M in cash with (24.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Briacell Therapeutics Probability Of Bankruptcy
Ownership AllocationBriacell Therapeutics holds a total of 36.18 Million outstanding shares. Briacell Therapeutics Corp shows 19.6 percent of its outstanding shares held by insiders and 5.67 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Briacell Ownership Details
Briacell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Concord Wealth Partners | 2024-09-30 | 14.1 K | |
| Susquehanna International Group, Llp | 2024-09-30 | 13.9 K | |
| Royal Bank Of Canada | 2024-09-30 | 3.8 K | |
| Td Waterhouse Canada Inc | 2024-09-30 | 2.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.7 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 1000 | |
| Hhm Wealth Advisors, Llc | 2024-09-30 | 1000 | |
| Ubs Group Ag | 2024-09-30 | 794 | |
| Simplex Trading, Llc | 2024-09-30 | 323 | |
| Vontobel Holding Ltd. | 2024-09-30 | 80 K | |
| Hrt Financial Llc | 2024-09-30 | 74.3 K |
Briacell Therapeutics Historical Income Statement
Briacell Stock Against Markets
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.